Total testosterone level Estradiol level Sex-
Conditions
Interventions
Participants(Gender dysphoria patients) will be received Estradiol valerate(4 mg daily) combined with Cyproterone acetate(25 mg daily) for cross-
sex hormone treatment.,Participants(Gender dysphoria patients) will be received Estradiol valerate(4 mg daily) combined with Spironolactone(100 mg daily) for cross-
sex hormone treatment.
Active Comparator Drug,Experimental Drug
Cyproterone acetate,Spironolactone
Sponsors
Ratchadapiseksompotch Fund, Faculty of Medicine
Ratchadapiseksompotch Fund,
Faculty of Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Gender dysphoria patients (Diagnosed from DSM V) Male to female transgender Not underwent orchidectomy No psychological disease or mental retardation
Exclusion criteria
Exclusion criteria: Anti-androgen usage 3 months prior to inclusion date History of active liver or kidney disease Diabetes type I, II Abnormal liver function test, Kidney function High serum potassium High prolactin level
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Testosterone level 3 months after intervention ECLIA of total testosterone level | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical and Metabolic changes 3 months after intervention Physical examination, Metabolic profile parameters | — |
Countries
Thailand
Contacts
Public ContactSupanut Burinkul
Chulalongkorn university
Outcome results
None listed